These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 1373255)
1. [Clodronate in the palliative therapy of bone-metastasized prostatic carcinoma]. Vorreuther R; Klotz T; Engelking R Urologe A; 1992 Mar; 31(2):63-6. PubMed ID: 1373255 [TBL] [Abstract][Full Text] [Related]
2. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. Heidenreich A; Hofmann R; Engelmann UH J Urol; 2001 Jan; 165(1):136-40. PubMed ID: 11125382 [TBL] [Abstract][Full Text] [Related]
3. Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Vorreuther R Br J Urol; 1993 Nov; 72(5 Pt 2):792-5. PubMed ID: 7506626 [TBL] [Abstract][Full Text] [Related]
4. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients. Rodrigues P; Hering F; Campagnari JC Prostate Cancer Prostatic Dis; 2004; 7(4):350-4. PubMed ID: 15534620 [TBL] [Abstract][Full Text] [Related]
5. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Kylmälä T; Tammela TL; Lindholm TS; Seppänen J Ann Chir Gynaecol; 1994; 83(4):316-9. PubMed ID: 7537482 [TBL] [Abstract][Full Text] [Related]
6. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. Piga A; Bracci R; Ferretti B; Sandri P; Nortilli R; Acito L; Pancotti A; Di Furia L; Carle F; Cellerino R J Exp Clin Cancer Res; 1998 Jun; 17(2):213-7. PubMed ID: 9700583 [TBL] [Abstract][Full Text] [Related]
7. Clodronate in the management of bone metastases: a clinical study of 91 patients. Serkies K; Jereczek-Fossa B; Badzio A; Jassem J Neoplasma; 1999; 46(5):317-22. PubMed ID: 10665850 [TBL] [Abstract][Full Text] [Related]
8. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071 [TBL] [Abstract][Full Text] [Related]
9. Disodium clodronate in the treatment of pain due to bone metastases. Luzzani M; Vidili MG; Rissotto R; Nobile MT; Beghè F; Rosso R; Gottlieb A Int J Clin Pharmacol Res; 1990; 10(4):243-6. PubMed ID: 2150406 [TBL] [Abstract][Full Text] [Related]
10. [Clodronate in treatment of tumor osteopathy. Evaluation in tumor patients with bone metastases or hypercalcemia]. Voigtmann R; Kirstein A Fortschr Med; 1994 Feb; 112(4):43-6. PubMed ID: 7512066 [TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070 [TBL] [Abstract][Full Text] [Related]
12. The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population. Santangelo A; Testai M; Barbagallo P; Manuele S; Di Stefano A; Tomarchio M; Trizzino G; Musumeci G; Panebianco P; Maugeri D Arch Gerontol Geriatr; 2006; 43(2):187-92. PubMed ID: 16325938 [TBL] [Abstract][Full Text] [Related]
13. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Strang P; Nilsson S; Brändstedt S; Sehlin J; Borghede G; Varenhorst E; Bandman U; Borck L; Englund G; Selin L Anticancer Res; 1997; 17(6D):4717-21. PubMed ID: 9494595 [TBL] [Abstract][Full Text] [Related]
14. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824 [TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates for cancer patients: why, how, and when? Body JJ; Mancini I Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of hormone-refractive prostatic carcinoma with painful bone metastasis. Epirubicin vs. clodronate vs. epirubicin plus clodronate]. Heidenreich A Urologe A; 1997 Nov; 36(6):568. PubMed ID: 9487597 [No Abstract] [Full Text] [Related]
17. Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Elomaa I; Blomqvist C; Porkka L; Lamberg-Allardt C; Borgström GH Bone; 1987; 8 Suppl 1():S53-6. PubMed ID: 2961355 [TBL] [Abstract][Full Text] [Related]
18. [Value of Clodronate in the treatment of bone metastasis]. Pouillart P; Beuzeboc P Bull Cancer; 1991; 78(8):737-41. PubMed ID: 1834287 [TBL] [Abstract][Full Text] [Related]
19. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708 [TBL] [Abstract][Full Text] [Related]
20. Clodronate for osteolytic metastases due to breast cancer. Elomaa I; Blomqvist C; Porkka L; Holmström T; Taube T; Lamberg-Allardt C; Borgström GH Biomed Pharmacother; 1988; 42(2):111-6. PubMed ID: 2971403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]